CHA Biotech said on the 3rd that its U.S. subsidiary Matica Biotechnology signed a CDMO (contract development and manufacturing) deal with Kalidi Biotherapeutics. Kalidi develops oncolytic virus therapies.
Matica Bio will support process development, manufacturing, and an investigational new drug application for "CLD-401," which Kalidi is developing. CLD-401 circulates throughout the body via intravenous injection, destroys cancer cells, and induces an immune response. Specific contract payments and details will not be disclosed by mutual agreement.
Matica Bio CEO Paul Kim said demand for CGT (cell and gene therapy) contract development and manufacturing is growing. Kalidi CEO Eric Foma said, "We expect to accelerate the development of oncolytic virus therapies."